Glutathione Status in Platelets From Patients With Type 2 Diabetes: Therapeutic Potential of N-acetylcysteine to Help Prevent Platelet Hyperaggregability - NAC study
- Conditions
- Platelet Aggregation in type 2 diabetes
- Registration Number
- EUCTR2008-001620-31-GB
- Lead Sponsor
- HS Highland
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 44
Men or post menopausal women with type 2 diabetes
Not recieving aspirin (group A)
Receiving Aspirin (Group B)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Very poorly controlled diabetes (HbA1c > 10%)
Significant hypertriglyceridaemia (TG > 4 mmol/L)
Renal disease (creatinine > 150 umol/L)
Current or recently stopped smokers (< 6 months)
Patients receiving other anti platelet therapy (i.e. clopidogrel, dipyridamole), or lipid lowering therapy where the patients are unable or unwilling to stop therapy for the duration of study participation.
Patients with asthma
Current use of tetracycline antibiotics or cough suppressants
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method